Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG ID6454

  • In development
  • GID-TA11592
  • Expected publication date: TBC

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6454

Referral

Topic selection